The Pharmaceutical Investment Business With Disease

  1. In order to understand such inconsistent action and to elucidate the goals of an organization that focuses on the promotion of ARV drugs and organizes rented crowds for the drug industry, it is critical to address the basic principles of the pharmaceutical investment business.
  2. The pharmaceutical business principals can be summarized as follows:
    1. The industry is not a health industry, but an investment business based on the return on investment from patented synthetic drugs.
    2. The marketplace of the pharmaceutical industry is diseases and their continuation and expansion are a precondition for the continuation of this investment business.
    3. Prevention and eradication of diseases narrow or eliminate these multi-billion Rand disease markets for the drug industry and are therefore being actively fought by these interests.
    4. Micronutrients and other science-based natural – but non-patentable – health approaches that help correct diseases at the cellular level are the single biggest threat for the survival of the multi-billion Rand investment business and are therefore the target of its most vicious attacks.
    5. In order to mask its deceptive nature – pretending to fight diseases whilst actually being dependant on their expansion – the pharmaceutical stakeholders use their profits to finance one of the largest and most comprehensive army of lobbyists influencing essentially all parts of societ

Criticism Of The Pharmaceutical Business With Disease
From Within The Medical Profession

  1. The first Respondent has been among the first to expose the pharmaceutical business with disease and its business principles characterized above. In the meantime, profound criticism of the unscrupulous business practices of the pharmaceutical investment industry has increased exponentially and has become the subject of many best-selling books.
  2. Particularly revealing has been the criticism from within the medical profession. A case in point is the book written by Dr Marcia Angell, M.D., the former editor in chief of the “New England Journal of Medicine”, the most influential medical journal in the world. Her book entitled: “The Truth About the Drug Companies – How They Deceive Us and What to Do About It” analyzes the pervasive influence of the pharmaceutical industry on medicine and society at large and is annexed to this response (Annexure ‘ Angell ’). Of particular interest are the following aspects:
    1. For more than two decades of work at the “New England Journal of Medicine,” including as editor in chief of this most influential medical journal in the world, Dr Angell has been a firsthand “eye witness” of the coercion of medicine by corporate greed on the part of the pharmaceutical industry.
    2. The harsh criticism of Dr Angell in her book about the business practices of the pharmaceutical industry has been translated in many languages and awarded, among others, by the “Polk Award,” one of the most coveted awards in journalism in the USA . Moreover, it has received wide support from leading newspapers, including the “New York Times” ( Annexure ‘Angell NYT ).
    3. Already in the introduction of her book Dr Angell clearly states: ”This book will expose the real pharmaceutical industry – an industry that over the past two decades has moved very far from its original high purpose of discovering and producing useful new drugs. Now primarily a marketing machine to sell drugs of dubious benefit this industry uses its wealth and power to co-opt every institution that might stand in its way, including the U.S. Congress, the food and drug administration, academic medical centres and the medical profession itself. Most of its marketing efforts are focused on influencing doctors, since they must write the prescriptions.” This statement bears particular relevance in light of the background to be revealed below about the current leadership of the South African Medical Association, one of the Applicants in this case.
    4. The significance of Dr Angell’s book about the unethical business practices of the drug companies has a particular significance for this case: Dr Angell’s “insider” report describes organizations, mechanisms and financial schemes which, as will be detailed in this response, are the hallmarks of organisations and individuals presented throughout this Application, including many of the “witnesses”. In light of this fact the following book chapters of Dr Angell are particularly relevant:
      1. “The $200 billion colossus”
        This chapter characterizing the pharmaceutical investment business corrects the perceived view of it as a “health industry” and describes the multinational drug companies as a “vast marketing machines with unprecedented control” over medicine, media, politics and – through this influence – on millions of people.
      2. “The Hard Sell … Lures, Bribes and Kickbacks”
        This chapter details the mechanisms by which this industry buys and coerces its influence on doctors and other health professionals to promote their often questionable drug merchandise.
      3. “Marketing Masquerading as Education”
        This important chapter describes the ruse applied by drug companies to cover their multi-billion rand drug marketing expenses as “medical education” efforts, including the use of “third party” organisations “conducting this education” seemingly independent of the drug influence. This is particularly relevant for this Application in light of the funding of organisations in South Africa like the “Foundation for Professional Development” which will be elucidated below in the context of documenting the background of the second Applicants.
      4. “Marketing Masquerading as Research”
        A second ruse beside “Education” that is being strategically used by the pharmaceutical industry to mask its drug marketing efforts is “research.” As we shall see, millions of rands are also channelled to South Africa and other developing countries to promote ARV drugs under the pretext of “charity” and supporting medical research.
      5. “Buying Influence – How the Industry Makes Sure It Gets Its Way”
        This chapter details the influence of the pharmaceutical investment business on many parts of society.